Katrin Giglhuber

Dr. Katrin Giglhuber

Technical University of Munich, Munich, Bavaria, Germany
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KGKatrin Giglhuber
Katrin Giglhuber
Achim BertheleAchim Berthele
Achim Berthele
Neuromyelitis optica spectrum disorders (NMOSD) are rare neurologic autoimmune diseases that have a poor prognosis if left untreated. For many years, generic oral immunosuppressants and repurposed monoclonal antibodies that target the interleukin-6 pathway or B cells were the mainstays of drug treatment. Recently, these drug treatments have been complemented by new biologics developed and approved specifically for NMOSD. In principle, all of these drugs are effective, but treatment recommendations that take this into account are still pending. Instead, the choice of a drug may depend on other criteria such as drug safety or tolerability. In this review, we summarise current knowledge on the adverse effects of azathioprine, mycophenolate mofetil, rituximab, tocilizumab, eculizumab, satralizumab, and inebilizumab in NMOSD. Infections, cytopenias, and infusion-related reactions are most common, but the data are as heterogeneous as the manifestations are diverse. Nevertheless, knowledge of safety issues may facilitate treatment choices for individual patients.

1 September 2015 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
Nico SollmannNico Sollmann
Nico Sollmann
KGKatrin Giglhuber
Katrin Giglhuber
LTLorena Tussis
Lorena Tussis
BMBernhard Meyer
Bernhard Meyer
FRFlorian Ringel
Florian Ringel
Sandro M KriegSandro M Krieg
Sandro M Krieg

11 July 2018 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
KGKatrin Giglhuber
Katrin Giglhuber
SMStefanie Maurer
Stefanie Maurer
CZClaus Zimmer
Claus Zimmer
BMBernhard Meyer
Bernhard Meyer
Sandro M KriegSandro M Krieg
Sandro M Krieg
Visuospatial attention is executed by the frontoparietal cortical areas of the brain. Damage to these areas can result in visual neglect. We therefore aimed to assess a combination of the greyscales task and repetitive navigated transcranial magnetic stimulation (rTMS) to identify cortical regions involved in visuospatial attention processes. This pilot study was designed to evaluate an approach in a cohort of healthy volunteers, with the future aim of using this technique to map brain tumor patients before surgery. Ten healthy, right-handed subjects underwent rTMS mapping of 52 cortical spots in both hemispheres. The greyscales task was presented tachistoscopically and was time-locked to rTMS pulses. The task pictures showed pairs of horizontal rectangles shaded continuously from black at one end to white at the other, mirror-reversed. On each picture the subject was asked to report which of the two greyscales appeared darker overall. The responses were categorized into “leftward” and “rightward,” depending on whether the subject had chosen the rectangle with the darker end on the left or the right. rTMS applied to cortical areas involved in visuospatial attention is supposed to affect lateral shifts in spatial bias. These shifts result in an altered performance on the greyscales task compared to the baseline performance without rTMS stimulation. In baseline conditions, 9/10 subjects showed classic pseudoneglect to the left. Leftward effects also occurred more often in mapping conditions. Yet, calculated rightward deviations were strikingly greater in magnitude (p < 0.0001). Overall, the right hemisphere was found to be more suggestible than the left hemisphere. Both rightward and leftward deviation scores were higher for the rTMS of this brain side (p < 0.0001). Right hemispheric distributions accord well with current models of visuospatial attention (Corbetta et al. Nat Neurosci 8(11):1603–1610, 2005). We observed leftward deviations triggered by rTMS within superior frontal and posterior parietal areas and rightward deviations within inferior frontal areas and the temporoparietal junction (TPJ). The greyscales task, in combination with rTMS, yields encouraging results in the examination of the visuospatial attention function. Future clinical implications should be evaluated.

18 January 2016 in Brain Imaging and Behavior
Verified
Journal Article
Closed access
PDF file
KGKatrin Giglhuber
Katrin Giglhuber
SMStefanie Maurer
Stefanie Maurer
CZClaus Zimmer
Claus Zimmer
BMBernhard Meyer
Bernhard Meyer
Sandro M KriegSandro M Krieg
Sandro M Krieg

10 June 2025 in European Journal of Neurology
Verified
Journal Article
Open access
DEDaniel Engels
Daniel Engels
CRChiara Rocchi
Chiara Rocchi
MFMirasol Forcadela
Mirasol Forcadela
PSPakeeran Siriratnam
Pakeeran Siriratnam
MRMarius Ringelstein
Marius Ringelstein
TKTania Kümpfel
Tania Kümpfel
Background: Aquaporin‐4‐IgG‐positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD) can cause significant disability after a single attack. Long‐term immunotherapy reduces disability accumulation, but the choice of first‐line therapy varies. In the United Kingdom, rituximab is typically used as escalation therapy after conventional immunosuppressants fail, while in Germany, it is widely used as first‐line treatment.Methods: We compared attack risk and disability outcomes based on the Expanded Disability Status Scale (EDSS) in AQP4‐IgG+ NMOSD patients treated with rituximab as first‐line versus escalation therapy. Furthermore, attack suppression and risk factors for attacks in individuals who received treatment with azathioprine and mycophenolate mofetil (with/without escalating to rituximab) were analyzed.Results: The risk of attack was lower in individuals who received rituximab as first‐line therapy (n = 52) compared to escalation therapy (n = 81, HR = 0.45, 95% CI = 0.30–0.67). Once escalated to rituximab, there was no altered risk of attack between first‐line rituximab and escalation therapy (HR = 1.15, 95% CI = 0.64–2.08). Rituximab as first‐line compared to escalation therapy was associated with lower EDSS scores at therapy start (3.0 vs. 6.0, p = 1.10 × 10−3). In patients who remained on azathioprine or mycophenolate mofetil (n = 45), age < 50 years and treatment with azathioprine were identified as risk factors for attacks.Conclusions: Rituximab as a first‐line therapy shows significant reduction in disability accumulation compared to escalation treatments. However, a subgroup of patients with AQP4‐IgG+ NMOSD may still respond well to conventional immunosuppression—specifically older patients treated with mycophenolate mofetil.

23 July 2025 in NeuroImage
Verified
Journal Article
Open access
TWTun Wiltgen
Tun Wiltgen
JMJulian McGinnis
Julian McGinnis
RBRonja Berg
Ronja Berg
CVCui Ci Voon
Cui Ci Voon
OPOula Puonti
Oula Puonti
MMMark Mühlau
Mark Mühlau
Conventional T1-weighted (T1w) magnetic resonance imaging (MRI) is commonly used in multiple sclerosis (MS) morphometry and volumetry research. However, arbitrary intensity scales preclude interpretation of signal values across patients, sites, and time. This requires quantitative MRI techniques, which are not always available. This study assessed T1w image intensity scaling methods, relying on extracerebral reference regions, for quantitative analysis of brain MRI in MS. In total, 701 people with a diagnosis of radiologically isolated syndrome, clinically isolated syndrome, or MS were included. Four intensity scaling strategies were applied: 1) MRI signal modeling, 2) linear scaling with reference regions, 3) z-score standardization, and 4) none (only bias field correction). Methods were evaluated using variance analysis, R1 map comparison, and normal-appearing white matter (NAWM) intensity group comparison, using mean and coefficient of variation (CoV), between low (≤3) and high (>3) expanded disability status scale (EDSS) scores. Statistical analysis was conducted using Pearson's r, two-sided Welch two-sample t-test, ANCOVA, and Cohen's d. Linear scaling with temporal fatty tissue achieved the most consistent variance reduction and strong correlation with R1 maps (r = 0.84). R1 values in NAWM were significantly lower in people with high compared to low EDSS scores (d = -0.351). Similarly, group differences in mean NAWM intensity of fat-scaled images were significant (d = -0.252). The largest group differences were found in NAWM CoV in bias field-corrected T1w images (d = 0.818). Linear scaling with fatty tissue most accurately reproduced the results obtained with R1 maps. Changes in MS NAWM appear to increase intensity variability detectable in conventional T1w images.